SiteOne Therapeutics Announces a $100 Million Series C Financing to Advance Selective Ion Channel Modulators as Non-opioid Treatments for PainSOUTH SAN FRANCISCO, Calif., December 18, 2024-- SiteOne Therapeutics, Inc., a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough, and other conditions, today announced a $100 million Series C financing.

2024年12月18日，SiteOne Therapeutics宣布了1亿美元的C系列融资，以推进选择性离子通道调节剂作为非阿片类药物治疗疼痛，加利福尼亚州旧金山南部——SiteOne Therapeutics，Inc.，一家开发用于治疗疼痛，咳嗽和其他疾病的选择性离子通道调节剂的生物制药公司，今天宣布了1亿美元的C系列融资。

Led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, BSQUARED Capital, and existing investors, the financing will support the advancement of SiteOne's portfolio of selective, small molecule ion channel modulators for the treatment of sensory hyperexcitability disorders through human clinical proof of concept..

在Novo Holdings的领导下，在OrbiMed、惠灵顿管理层、Mission BioCapital、BSQUARED Capital和现有投资者的参与下，该融资将支持SiteOne选择性小分子离子通道调节剂投资组合的发展，通过人类临床概念验证来治疗感觉过度兴奋性疾病。

In conjunction with the financing, SiteOne Therapeutics appointed to its Board of Directors: Ken Harrison, Ph.D., Senior Partner at Novo Holdings; Mona Ashiya, Ph.D., Partner at OrbiMed; and Zach Collins, Ph.D., Partner at Mission BioCapital. In addition, Praveen Tipirneni, M.D., most recently CEO of Morphic Therapeutic, has joined the Board as Executive Chairperson, and Martin Edwards, M.D., an experienced life science advisor, has joined as an independent Board member..

在融资的同时，SiteOne Therapeutics被任命为董事会成员：Ken Harrison博士，Novo Holdings的高级合伙人；Mona Ashiya博士，OrbiMed合伙人；和Mission BioCapital合伙人扎克·柯林斯博士。此外，最近担任Morphic Therapy首席执行官的医学博士Praveen Tipirneni已加入董事会，担任执行主席，经验丰富的生命科学顾问Martin Edwards医学博士已加入董事会，担任独立董事。

“SiteOne Therapeutics is committed to developing non-opioid treatments for conditions that involve hyperexcitability of the peripheral nervous system such as pain and cough. Our strategy is focused on owning the action potential, the fundamental unit of electrical signaling in the peripheral nervous system.

“SiteOne Therapeutics致力于开发非阿片类药物治疗，以治疗涉及周围神经系统过度兴奋的疾病，如疼痛和咳嗽。我们的策略是专注于拥有动作电位，这是周围神经系统电信号的基本单位。

This funding will enable human proof of concept studies on our isoform-selective sodium channel inhibitors and development of other ion channel modulators,” commented John Mulcahy, Ph.D., President and Chief Executive Officer of SiteOne Therapeutics. “SiteOne welcomes Ken Harrison, Mona Ashiya, Zach Collins, Martin Edwards, and Praveen Tipirneni as members of our Board of Directors.

这笔资金将使人类能够对我们的同工型选择性钠通道抑制剂进行概念验证研究，并开发其他离子通道调节剂，”SiteOne Therapeutics总裁兼首席执行官John Mulcahy博士评论道。“SiteOne欢迎Ken Harrison、Mona Ashiya、Zach Collins、Martin Edwards和Praveen Tipirneni担任董事会成员。

Their collective expertise in drug development, commercial strategy, capital markets and business development will be pivotal as we build out our team and advance our small molecule candidates in the clinic.”.

他们在药物开发，商业战略，资本市场和业务发展方面的集体专业知识将是我们建设团队并在临床上推进小分子候选人的关键。”

SiteOne’s approach is grounded in the development of selective best-in-class sodium channel inhibitors, including NaV1.7 and NaV1.8. The company’s lead program for pain targets the NaV1.8 channel, which is primarily located in the peripheral nervous system, and has the potential to provide meaningful analgesia with a reduced side effect profile and risk of abuse compared to current, central nervous system-focused standard-of-care.

SiteOne的方法基于选择性最佳钠通道抑制剂的开发，包括NaV1.7和NaV1.8。该公司的疼痛主导计划针对NaV1.8通道，该通道主要位于周围神经系统，与目前以中枢神经系统为重点的标准护理相比，有可能提供有意义的镇痛，减少副作用和滥用风险。

Beyond pain, SiteOne is exploring the potential of sodium channels and other genetically and clinically validated targets to treat pain and sensory hyperexcitability disorders..

除了疼痛，SiteOne正在探索钠通道和其他经过基因和临床验证的靶点治疗疼痛和感觉过度兴奋性疾病的潜力。

Ken Harrison, Senior Partner, Novo Holdings, stated, “SiteOne Therapeutics’ portfolio of selective ion channel modulators holds immense promise for the non-opioid treatment of pain. SiteOne has built upon years of research on the contribution of ion channels to peripheral nerve excitability, and we are very encouraged by the company’s underlying science and its mission to transform pain management for patients living with chronic pain in the US and around the globe.”.

Novo Holdings高级合伙人肯·哈里森（Ken Harrison）表示：“SiteOne Therapeutics的选择性离子通道调节剂组合在非阿片类药物治疗疼痛方面具有巨大的前景。SiteOne建立在多年来对离子通道对周围神经兴奋性贡献的研究基础上，我们对该公司的基础科学及其在美国和全球范围内改变慢性疼痛患者疼痛管理的使命感到非常鼓舞。”

“While many companies are focused on drug discovery for the central nervous system, SiteOne is instead pursuing a pipeline of therapeutics that specifically target the peripheral nervous system,” added Praveen Tipirneni. “By targeting peripheral sensory neurons directly, SiteOne is positioned to develop complementary, robust treatments for pain and other sensory hyperexcitability disorders without the centrally mediated side effects of existing therapeutics.

Praveen Tipirneni补充道：“虽然许多公司专注于中枢神经系统的药物发现，但SiteOne正在寻求专门针对周围神经系统的治疗方法。”。“通过直接针对外周感觉神经元，SiteOne可以开发针对疼痛和其他感觉过度兴奋性疾病的补充，强大的治疗方法，而不会产生现有治疗方法的中枢介导的副作用。

I am excited to join SiteOne as they continue to develop these important therapeutics for the potential benefit of millions of patients.”.

我很高兴加入SiteOne，因为他们将继续开发这些重要的治疗方法，为数百万患者带来潜在的益处。”

About Novo Holdings A/S

关于Novo Holdings A/S

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.

诺和诺德控股公司是一家控股和投资公司，负责管理诺和诺德基金会的资产和财富。诺和诺德控股的目的是通过对诺和诺德基金会的资产产生有吸引力的长期回报，改善人们的健康以及社会和地球的可持续性。

Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor.

Novo Holdings是诺和诺德基金会（Novo Nordisk Foundation）的全资子公司，是诺和诺德股份有限公司（Novo Nordisk A/S）和诺和诺西股份有限公司（Novonesis A/S）的控股股东，管理着一个具有长期回报前景的投资组合。除了管理广泛的股票、债券、房地产、基础设施和私人股本资产组合外，Novo Holdings是世界领先的生命科学投资者。

Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2023, Novo Holdings had total assets of EUR 149 billion. www.novoholdings.dk.

Novo Holdings通过其种子、风险投资、增长、亚洲、行星健康和主要投资团队，在生命科学公司的各个发展阶段进行投资。截至2023年底，Novo Holdings的总资产为1490亿欧元。www.novoholdings.dk。

About SiteOne Therapeutics

关于SiteOne Therapeutics

SiteOne Therapeutics is a biopharmaceutical company advancing a novel class of highly selective small molecule inhibitors targeting NaV1.7, NaV1.8, and other voltage-gated ion channels to treat sensory hyperexcitability disorders such as chronic cough, itch, and pain. Since its inception, SiteOne has been dedicated to the development of safe and effective pain therapeutics without the significant addiction potential and side effects of opioids.

SiteOne Therapeutics是一家生物制药公司，开发了一类针对NaV1.7，NaV1.8和其他电压门控离子通道的新型高选择性小分子抑制剂，用于治疗感觉过度兴奋性疾病，如慢性咳嗽，瘙痒和疼痛。自成立以来，SiteOne一直致力于开发安全有效的疼痛治疗药物，而没有阿片类药物的显着成瘾潜力和副作用。

The company is also advancing additional novel drug candidates that exhibit precise selectivity for individual ion channel subtypes to treat other sensory hyperexcitability disorders such as chronic cough and chronic ocular surface pain. For more information, visit www.siteonetherapeutics.com.Contact: .

该公司还推出了其他新型候选药物，这些候选药物对单个离子通道亚型具有精确的选择性，可治疗其他感觉过度兴奋性疾病，如慢性咳嗽和慢性眼表疼痛。有关更多信息，请访问www.siteonetherapeutics.com.Contact：。

Company: info@site1therapeutics.com

公司名称：info@site1therapeutics.com

Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091

媒体：杰西卡·英玲博士，小狗通信公司。，jessica@litldog.com，+1.858.344.8091